C07D 237/00
Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
C07D237/00 (Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings) appears on 2,240 US grants and 2,053 published applications in this corpus.
Search patents in C07D- Granted patents
- 2,240
- Published applications
- 2,053
- Assignees
- 962
- Inventors
- 7,675
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 18 | 0 |
| 1977 | 18 | 0 |
| 1978 | 28 | 0 |
| 1979 | 18 | 0 |
| 1980 | 24 | 0 |
| 1981 | 27 | 0 |
| 1982 | 28 | 0 |
| 1983 | 22 | 0 |
| 1984 | 16 | 0 |
| 1985 | 22 | 0 |
| 1986 | 38 | 0 |
| 1987 | 48 | 0 |
| 1988 | 39 | 0 |
| 1989 | 47 | 0 |
| 1990 | 48 | 0 |
| 1991 | 40 | 0 |
| 1992 | 41 | 0 |
| 1993 | 34 | 0 |
| 1994 | 30 | 0 |
| 1995 | 35 | 0 |
| 1996 | 31 | 0 |
| 1997 | 37 | 0 |
| 1998 | 47 | 0 |
| 1999 | 41 | 0 |
| 2000 | 36 | 0 |
| 2001 | 45 | 5 |
| 2002 | 48 | 38 |
| 2003 | 35 | 62 |
| 2004 | 36 | 84 |
| 2005 | 32 | 100 |
| 2006 | 40 | 65 |
| 2007 | 51 | 65 |
| 2008 | 44 | 96 |
| 2009 | 52 | 83 |
| 2010 | 53 | 92 |
| 2011 | 50 | 85 |
| 2012 | 55 | 60 |
| 2013 | 61 | 78 |
| 2014 | 62 | 103 |
| 2015 | 105 | 90 |
| 2016 | 75 | 94 |
| 2017 | 101 | 99 |
| 2018 | 82 | 86 |
| 2019 | 62 | 66 |
| 2020 | 54 | 85 |
| 2021 | 53 | 88 |
| 2022 | 57 | 82 |
| 2023 | 40 | 110 |
| 2024 | 40 | 98 |
| 2025 | 51 | 80 |
| 2026 | 43 | 59 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Membrane-active anti-bacterial compounds and uses thereof29 Sep 2026US 12,747,213 B2Regents of the University of Minnesota
- N2-arylmethyl-4-haloalkyl-pyridazin-3-one CFTR modulators for the treatment of cystic fibrosis29 Sep 2026US 12,747,215 B2Centre National de la Recherche Scientifique (CNRS)
- EAAT2 activators and methods of using thereof29 Sep 2026US 12,747,227 B2Ohio State Innovation Foundation
- Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents22 Sep 2026US 12,740,943 B2ModernaTX, Inc.
- Substituted pyridazine compound22 Sep 2026US 12,741,942 B2Tenvie Therapeutics, Inc.
- Method for Treating Phosphorus-Containing Wastewater Produced During Preparation of Sulfonamide Compound8 Oct 2026US 2026/0308035 A1Nanhai Beisha Pharmaceutical Co., Ltd.
- Compound as voltage-gated sodium channel inhibitor3 Sep 2026US 2026/0257996 A1Guangzhou Fermion Technology Co., Ltd.
- Process for the preparation of (6s,9r)-3-oxo-3,5,6,7,8,9-hexahydro-2h-6,9-epiminocyclohepta[c]pyridazine-10-carboxamide derivatives3 Sep 2026US 2026/0258043 A1Pathios Therapeutics Limited
- Pharmaceutical compositions for subcutaneous administration of levosimendan27 Aug 2026US 2026/0248785 A1Tenax Therapeutics, Inc.
- Small molecule inhibitors of the bfrb:bfd interaction20 Aug 2026US 2026/0240813 A1Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Most cited
By later US patents
- Heterogenous specific binding assay employing a cycling reactant as label151US 4,318,980 AMiles Laboratories, Inc. · 1982
- Modulators of ATP-binding cassette transporters118US 7,598,412 B2Vertex Pharmaceuticals Incorporated · 2009
- Chemical compounds as inhibitors of amyloid beta protein production110US 5,624,937 AEli Lilly and Company · 1997
- Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals99US 5,658,933 AHoechst Aktiengesellschaft · 1997
- Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process91US 5,177,075 AWarner-Lambert Company · 1993